Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib or placebo plus capecitabine in previously treated advanced pancreatic adenocarcinoma
2014-000294-39Phase 3Completed
- Sponsor
- Incyte
- Start
- May 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) comparing Ruxolitinib + capecitabine with Placebo + capecitabine (2 arms). Primary endpoint: Overall survival. Started May 2014; status: completed.
02
Drugs
ruxolitinibcapecitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2014-000294-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000294-39.